We are committed to serving the best interests of our shareholders.

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary EXCLUSIVE LICENSE AGREEMENT WITH AMGEN TO ACQUIRE RIGHTS TO ANAPLASTIC LYMPHOMA KINASE (ALK) PROGRAM
TESARO will be responsible for worldwide development and commercialization Amgen's oral, small molecule ALK inhibitors are highly potent and selective, and possess desirable pharmaceutical properties Recent clinical proof-of-concept has been demonstrated for ALK inhibition in patients with ALK
View HTML
Toggle Summary TESARO AND OPKO HEALTH SIGN EXCLUSIVE LICENSE AGREEMENT FOR
Rolapitant is a Phase III-ready neurokinin-1 (NK-1) receptor antagonist in development for chemotherapy induced nausea and vomiting (CINV) TESARO will be responsible for worldwide development and commercialization Boston, MA and Miami, FL – December 14, 2010 – TESARO, Inc.
View HTML
Toggle Summary TESARO, INC. SECURES $60 MILLION IN START-UP FUNDING
Former MGI PHARMA Executives Found New Oncology-Focused Biopharma Company Initial Financing Provided by New Enterprise Associates (NEA) and Management Boston, MA – May 26, 2010 – TESARO, Inc., an oncology-focused biopharmaceutical company, today announced that it has secured $60 million
View HTML